Aptose Biosciences (NASDAQ:APTO) Upgraded to “Strong-Buy” at Alliance Global Partners

Alliance Global Partners upgraded shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) to a strong-buy rating in a research report released on Thursday,Zacks.com reports.

Other research analysts have also recently issued reports about the stock. HC Wainwright reiterated a “buy” rating and set a $60.00 target price on shares of Aptose Biosciences in a report on Wednesday, February 12th. StockNews.com started coverage on shares of Aptose Biosciences in a research report on Tuesday. They issued a “hold” rating for the company. One analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Aptose Biosciences currently has a consensus rating of “Buy” and an average price target of $130.00.

Aptose Biosciences Trading Down 1.8 %

Shares of APTO stock opened at $3.19 on Thursday. The stock has a market capitalization of $6.83 million, a price-to-earnings ratio of -1.07 and a beta of 0.88. Aptose Biosciences has a twelve month low of $3.05 and a twelve month high of $57.00. The stock has a fifty day simple moving average of $5.92 and a two-hundred day simple moving average of $8.83.

Institutional Investors Weigh In On Aptose Biosciences

A hedge fund recently bought a new stake in Aptose Biosciences stock. Bleichroeder LP purchased a new stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 2,500,000 shares of the biotechnology company’s stock, valued at approximately $563,000. Bleichroeder LP owned about 4.15% of Aptose Biosciences as of its most recent filing with the Securities & Exchange Commission. 26.62% of the stock is currently owned by institutional investors.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.